This inventor holds 1 USPTO granted patent. Top assignee: Mitsui Toatsu Chemicals, Incorporated. Active years: 1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1998
Title: Noboru Satozawa: Innovating Vascularization Inhibition with Human Monoclonal Antibodies
Introduction
Noboru Satozawa, a notable inventor from Chiba-ken, Japan, has made significant contributions in the field of biotechnology. With a focus on developing therapeutic solutions, Satozawa holds a patent that stands to impact the treatment of diseases associated with abnormal vascularization.
Latest Patents
Satozawa's patent, an anti-VEGF (Vascular Endothelial Growth Factor) human monoclonal antibody, provides a crucial advancement in neutralizing VEGF activity. This invention includes not just the antibody itself but also a cell strain that produces it, along with methods to inhibit vascularization effectively. By transforming human lymphocytes producing anti-human VEGF antibodies with Epstein-Barr Virus (EBV) and subsequently fusing them with human myeloma cells, Satozawa has paved the way for creating hybridoma strains, namely VA01 and BL2. With its human origin, this monoclonal antibody specifically binds to VEGF, inhibiting the proliferation and migration of vascular endothelial cells, thus proving to be a valuable vascularization inhibitor for therapeutic use.
Career Highlights
Noboru Satozawa is currently engaged with Mitsui Toatsu Chemicals, Incorporated, where he channels his expertise towards innovative research in the field of biotechnology. His work revolves around the development of monoclonal antibodies and their applications, showcasing his dedication to scientific advancement and improving human health outcomes.
Collaborations
Throughout his career, Satozawa has collaborated with notable colleagues, including Hisayoshi Ooka and Shiro Takagi. These partnerships demonstrate the importance of teamwork in the pursuit of groundbreaking inventions and signify a shared commitment to the scientific community.
Conclusion
Noboru Satozawa stands as a prominent figure in the realm of biomedical innovations, particularly through his pioneering work on anti-VEGF human monoclonal antibodies. His contributions not only highlight the potential of patenting inventions in biotechnology but also illustrate the collaborative efforts that are essential in driving innovation forward.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile